188 related articles for article (PubMed ID: 23796987)
21. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
Engert A; Josting A; Haverkamp H; Villalobos M; Lohri A; Sökler M; Zijlstra J; Sturm I; Topp MS; Rank A; Zenz T; Vogelhuber M; Nogova L; Borchmann P; Fuchs M; Flechtner HH; Diehl V
J Clin Oncol; 2010 May; 28(13):2239-45. PubMed ID: 20368566
[TBL] [Abstract][Full Text] [Related]
22. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
23. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N
Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498
[TBL] [Abstract][Full Text] [Related]
24. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
[TBL] [Abstract][Full Text] [Related]
25. The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma.
Gobbi PG; Rosti V; Valentino F; Bonetti E; Merli F; Stelitano C; Dondi A; Quarta G; Falorio S; Federico M
Clin Lymphoma Myeloma; 2009 Dec; 9(6):425-9. PubMed ID: 19951881
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of advanced Hodgkin lymphoma].
Kreissl S; Borchmann P
Dtsch Med Wochenschr; 2013 Jun; 138(23):1212-4. PubMed ID: 23720173
[No Abstract] [Full Text] [Related]
27. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
[TBL] [Abstract][Full Text] [Related]
28. Which Hodgkin's patients in the Unites States should be treated with BEACOPP?
Cheson BD
Curr Hematol Malig Rep; 2014 Sep; 9(3):222-6. PubMed ID: 24879421
[TBL] [Abstract][Full Text] [Related]
29. Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis.
Fosså A; Fiskvik IH; Kolstad A; Lauritzsen GF; Aurlien E; Blystad AK; Hole KH; Ikonomou IM; Holte H
Ann Oncol; 2012 May; 23(5):1254-1259. PubMed ID: 21926399
[TBL] [Abstract][Full Text] [Related]
30. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
31. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?
Diehl V; Behringer K
Cancer Invest; 2006; 24(4):461-5. PubMed ID: 16777701
[TBL] [Abstract][Full Text] [Related]
32. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
33. Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey.
Boltežar L; Pintarić K; Jezeršek Novaković B
J Assist Reprod Genet; 2016 Mar; 33(3):325-333. PubMed ID: 26678493
[TBL] [Abstract][Full Text] [Related]
34. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
Sieniawski M; Reineke T; Nogova L; Josting A; Pfistner B; Diehl V; Engert A
Blood; 2008 Jan; 111(1):71-6. PubMed ID: 17890456
[TBL] [Abstract][Full Text] [Related]
35. 'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma-A multicentre, retrospective study.
Wilson MR; Haynes E; Parsons K; Hopkins D; Robertson E; Ferguson G; Quinn D; Murray J; Osborne W; Leach M; McKay P
Br J Haematol; 2023 Aug; 202(4):796-800. PubMed ID: 37357380
[TBL] [Abstract][Full Text] [Related]
36. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?
Diehl V; Behringer K
Cancer Invest; 2006 Nov; 24(7):713-7. PubMed ID: 17118782
[TBL] [Abstract][Full Text] [Related]
37. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Scholz M; Engert A; Franklin J; Josting A; Diehl V; Hasenclever D; Loeffler M
Ann Oncol; 2011 Mar; 22(3):681-688. PubMed ID: 20720088
[TBL] [Abstract][Full Text] [Related]
38. Sarcoidosis following escalated BEACOPP chemotherapy for stage IV Hodgkin lymphoma.
Cho KK; Lyes SM; Shetty A
Intern Med J; 2019 Apr; 49(4):547-548. PubMed ID: 30957369
[No Abstract] [Full Text] [Related]
39. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors.
Avivi I; Hardak E; Shaham B; Igla M; Rowe JM; Dann EJ
Ann Hematol; 2012 Feb; 91(2):215-21. PubMed ID: 21603918
[TBL] [Abstract][Full Text] [Related]
40. ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.
Amin MSA; Brunckhorst O; Scott C; Wrench D; Gleeson M; Kazmi M; Ahmed K
Clin Transl Oncol; 2021 Jun; 23(6):1067-1077. PubMed ID: 32944834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]